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Early response prediction is considered an essential tool to obtain a more customized anticancer treatment because it allows for 
the identification of patients who will benefit most from a particular therapy and prevents the exposure of those patients to toxic, 
non-effective regimens. Recent discoveries of novel markers in functional imaging have created exciting opportunities for in vivo 
visualization and quantification of cell death. This review will focus on in vivo apoptosis imaging with various radiotracers as predic-
tive tools for tumor response after anticancer therapy. Particular focus will be on annexin V imaging, a technique with the largest 
clinical experience to date. This article is part of a Special Issue entitled “Apoptosis: Four Decades Later”.
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INTRODUCTION
Apoptosis is an evolutionary highly preserved and 
well-orchestrated �iological process involved in �oth 
physiological and pathological conditions� and there-
fore possi�ly the most a�undant form of programmed 
cell death [�]. Therapy-induced apoptosis in vivo 
has �een shown to significantly contri�ute to tumor 
response [�� �] and to correlate with su�sequent 
outcome [���]. After �� years of intense research� 
apoptosis is now considered not only as a fundamental 
process leading to disorders of normal tissues [����]� 
�ut also as a form of cell death in response to oncolytic 
therapies [�����]. 
Apoptosis can �e triggered �y exogenous and 
endogenous stimuli leading to the activation of the ex-
trinsic and intrinsic pathways of apoptosis� respectively 
�Fig. ��. These pathways converge at the activation 
of a su�set of proteases� the executioner caspase-�� 
-� and -�� targeting specific intracellular proteins such 
as those involved in DNA damage repair and cellular 
cytoskeleton.
The extrinsic pathway is engaged �y �inding of spe-
cific death ligands to specific death receptors on the 
cell mem�rane� such as tumor necrosis factor a �TNF-
a�� TNF-related apoptosis-inducing ligand �TRAIL�� 
Fas ligand �FasL� to TNF receptor � �TNFR��� death 
receptor � or death receptor 5 �DR� or DR5� and Fas/
CD�5 receptor� respectively. Death receptor-ligand 
�inding recruits an intracellular adaptor molecule� 
TNF-receptor-associated death domain �TRADD� 
or Fas-associated death domain �FADD� via its cy-
toplasmic death domain �DD�� clustering to form the 
death-inducing signaling complex �DI�C� which in turn 
recruits and activates cytoplasmic pro-apoptotic cas-
pase-8 �initiator caspase� via its death effector domain 
�DED�. This is followed �y the sequential activation 
of downstream executioner caspase-�� -�� and -�. 
Activated caspase-� translocates to the nucleus and 
activates poly-ADP-ri�ose polymerase �PARP-��� 
which facilitates the degradation of nuclear DNA into 
5� to ��� kilo�ase-sized fragments. 
Anticancer drugs and ionizing radiation utilize the 
intrinsic pathway to trigger apoptosis. This process 
involves mitochondrial outer mem�rane permea�ili-
zation and the su�sequent release of pro-apoptotic 
factors� including cytochrome c� into the cytosol. Cy-
tochrome c interacts with Apaf-� �apoptotic activating 
factor-��� ATP� and procaspase-� to form a complex 
known as the apoptosome which in turn activates 
caspase-� and further activates the executioner cas-
pase-�� -�� and -�� generating a variety of molecular 
damages in essentially every organelle. In terms of cell 
survival� however� it is the damage to DNA leading 
to the loss of proliferative and clonogenic capac-
ity that is most important. Although chemotherapy 
and radiotherapy-induced apoptosis is a caspase-
dependent process [�5��8]� it is unclear how cel-
lular signals from DNA lesions lead to the execution 
of apoptosis. �ince Bcl-� is a�le to �lock cytochrome 
c release and prevent apoptosis� it has �een proposed 
that anticancer therapy-induced caspase activation 
is mitochondria dependent [��� �����]. This concept 
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is further su�stantiated �y the o�servation that activa-
tion of p5� �y anticancer therapy due to DNA damage 
is a direct transcriptional regulator of Bcl-�� Bax� Puma� 
Noxa and Bid and can act as an apoptogenic factor 
at the mitochondrial mem�rane [����5]. Furthermore� 
there are functional connections �etween p5� and 
death receptors genes �CD�5 and TRAIL receptor-�� 
that can �e upregulated in response to therapy [��� 
��]� in turn leading to the activation of inducer cas-
pase-8. It has also �een shown that pretreatment 
of cells with DNA damaging agents improves the ca-
pacity of TRAIL-�ound receptors to recruit FADD and 
activate caspase-8 and -�� in the DI�C� irrespective 
of p5� status [�8].
As apoptosis has �een recognized as a major 
form of cell death after anticancer therapy� it is �eing 
increasingly evaluated as a prognostic marker of treat-
ment outcome. For this purpose� a noninvasive method 
to analyze treatment-induced apoptosis is most at-
tractive� as it can �e used to determine and predict the 
effectiveness of an anticancer regime. In this review� 
we will discuss apoptosis imaging modalities in �oth 
animal models and patients using annexin V� detection 
of apoptotic mem�rane imprint� methoxyiso�utylisoni-
trile �MIBI�� and the novel caspase-� small-molecule 
inhi�itor� Isatin� and address their a�ility to improve 
patient treatment �see Fig. ��. Annexin V scintigraphy� 
an imaging technique for which we have the most clini-
cal experience with� will especially �e detailed in this 
discussion. 
IMAGING OF APOPTOSIS USING ANNEXIN V
Annexin V-�ased tracers are the most frequently 
used agents for in vitro detection and quantification 
of apoptotic cells. This is �ased on the high affinity 
of annexin V for the mem�rane �ound phospholipid 
�P��� which in via�le cells� resides in the inner leaflet 
of the plasma mem�rane. Upon exposure of cells 
to apoptotic stimuli g-scram�lase is activated result-
ing in P� flipping to the outer leaflet of the plasma 
mem�rane� there�y allowing annexin V to �ind 
to P�. In addition� it has �een shown that mem-
�rane �inding of proteins that recognize exposed 
P� on apoptotic cells is regulated �y the transmem-
�rane potential [��]. A decreasing mem�rane potential 
in Jurkat T leukemia cells and K5�� promyelocytic 
leukemia cells undergoing apoptosis increases the 
extracellular �inding of annexin V in a dose-dependent 
manner. �tudies with P� vesicles also showed that 
the mem�rane potential increases the �inding affinity 
of annexin V for the P� cell surface molecules.
Single photon emission computed tomography 
(SPECT) 
��mTechnetium-linked annexin V has �een exten-
sively used in apoptosis detection in patients� exploit-
ing its optimal radionuclidic properties for �PECT 
Fig. 1. Imaging of apoptosis �y various radiotracers. While annexin V �ased compounds and Apo�ense agents work at the 
level of the cell plasma mem�rane� MIBI acts at the mitochondria and Isatin targets executioner caspase � �DR=Death Receptor; 
PARA=Pro-Apoptotic Receptor Agonist�. Inserts are examples of images acquired �y the indicated modalities. Modified from: 
Haimovitz-Friedman et al.� ���� [��]
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imaging� relative low costs and easy availa�ility [��]. 
In ���5� �tratton et al. [��] were the first to demon-
strate ��mTc-annexin V’s value for the in vivo detection 
of mem�rane-associated P� exposure using �PECT 
�y injecting ��mTc-la�eled human annexin V intrave-
nously and calculating the atrial throm�us/�lood ratio 
in throm�o-em�olic diseases. Other �PECT studies 
using ��mTc-annexin V derivatives provided feasi�i-
lity and potential clinical utility of apoptosis imaging 
in various other medical disorders [��]. Multiple con-
jugators of annexin V have �een developed� including 
��5-�is�thioacetamido�pentanoyl �BTAP� for its rapid 
and extensive radioactivity accumulation in the gastro-
intestinal tract. �ince this tracer was mainly excreted 
�y the liver and the kidneys� resulting in an increased 
radionuclide accumulation in these organs as well 
[��]� the role of ��mTc-BTAP annexin V for a�dominal 
imaging was limited. 
Blanken�erg et al. [��] su�sequently coupled 
annexin V to hydrazinonicotinamide and created 
��mTc-HYNIC annexin V. In vivo studies using a CD�5L-
induced hepatocyte apoptosis mouse model with 
intravenously administered anti-CD�5 anti�ody dem-
onstrated that ��mTc-HYNIC annexin V can �e used 
to image apoptotic �and necrotic� cell death in vivo. 
Although the concentration of tracer in liver and 
kidneys were still high� and similar to ��mTc-BTAP an-
nexin V� radioactivity accumulation in the �owel was 
eradicated� making it a suita�le candidate tracer 
for a�dominal examination [�5]. Following further 
optimization of image quality� ��mTc-annexin V proves 
to �e an effective modality for non-invasive evalua-
tion of cell death and treatment response in allograft 
rejection� myocardial infarction� reperfusion injury and 
infectious disease [����8]. 
99mTc-annexin V studies in combination with 
anticancer therapy
The first in vivo demonstration of anticancer therapy-
induced apoptosis involved the use of ��mTc-annexin 
V in an experimental mouse lymphoma model treated 
with cyclophosphamide. The animals treated with che-
motherapy demonstrated a more than ���% increase 
in annexin V uptake �� h after treatment compared 
to untreated animals [��]. More recently� the value 
of ��mTc-annexin V imaging in response monitoring 
was evaluated in a mouse model for hereditary �reast 
cancer after docetaxel treatment [��]. The sensitive 
tumors showed an increase in ��mTc-annexin V uptake 
and immunohistochemical evidence of apoptosis one 
day post-treatment. On the other hand� resistant tumors 
showed neither an increase in ��mTc-annexin V uptake 
nor significant immunohistochemical changes �Fig. ��. 
Despite these encouraging findings� ��mTc-annexin 
V ima ging could not �e used to predict tumor response� 
due to large variations in uptake �etween animals.
In addition to animal studies� annexin V imaging has 
also �een applied in various clinical protocols. In ����� 
��mTc-annexin V was first used in clinical trials with pa-
tients scheduled to receive chemotherapy for locally 
advanced or metastatic non-small cell lung cancer 
�N�CLC�� small cell lung cancer ��CLC�� Hodgkin �HL� 
and non-Hodgkin �NHL� lymphoma� and �reast cancer. 
Fifteen patients underwent ��mTc-annexin V scintigra-
phy �efore and within � days after their first course 
of chemotherapy. Patients with lung cancer received 
platinum-�ased chemotherapy� lymphoma patients 
were treated with vincristine or cyclophosphamide-
�ased chemotherapy and �reast cancer patients 
received taxane as their chemotherapy regime. Five 
patients had increased annexin V uptake ����8 hours 
after chemotherapy �� NHL� � HL� � �CLC� and 
� N�CLC�� and � patients showed increased uptake 
����� hours after treatment �� N�CLC� � �CLC�. 
At the median follow-up of ��� days� while patients 
with no change in radiotracer uptake after the first 
cycle of chemotherapy had no su�sequent o�jective 
clinical response� patients demonstrating increased 
tracer uptake post-treatment had either a partial 
or complete tumor response. From these results� it was 
concluded that ��mTc-annexin V could �e used clini-
cally for in vivo imaging of apoptosis after one course 
of chemotherapy [��].
a
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Fig. 2. Preclinical imaging of apoptosis. Quantitative whole ani-
mal ��mTc-annexin V �PECT imaging and histology of a T*�� sen-
sitive �a� and resistant tumor �b�� o�tained �efore and � day after 
docetaxel treatment. Right panel: tumors were stained for TUNEL 
at day �. Modified from: Beekman et al.� ���� [��]
One of the first reports on the application of ��mTc-
annexin V in patients receiving radiotherapy was 
�y Haas et al. [��] who applied ��mTc-annexin V scin-
tigraphy �TAV�� to monitor radiation-induced apoptotic 
cell death in �� follicular lymphoma patients �Fig. ��. All 
patients underwent a �aseline scan within one week 
prior to the start of radiotherapy to detect �aseline 
levels of spontaneous tumor apoptosis or necrosis. Pa-
tients were then irradiated to the involved lymph node 
areas to a total dose of � Gy in � fractions �8 h apart. 
At �� h after the second radiation fraction� TAV� was 
repeated. Fine needle aspiration cytologic analysis 
for apoptosis was also performed prior to� during and 
after irradiation. In �� patients� post-treatment TAV� 
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matched the post-treatment cytology� confir ming 
TAV� as a valua�le non-invasive method to detect 
in vivo apoptosis caused �y radiation. In addition� the 
increase in ��mTc-annexin V uptake post-treatment 
in this type of malignancy correlated with clinical 
outcome: all patients with prominent cytologic and 
scintigraphic signs of apoptosis achieved complete 
remission within � week. 
In ����� Kartachova et al. [��] from the Nether-
lands Cancer Institute conducted a study of �� patients 
with malignant lymphoma� leukemia� N�CLC� and head 
and neck squamous cell carcinoma �HN�CC� sched-
uled for radiotherapy� platinum-�ased chemotherapy� 
or concurrent chemoradiation �see Fig. ��. 
Fig. 3. Typical examples of anticancer therapy-induced apop-
tosis as demonstrated �y in vivo annexin V scintigraphy. �hown 
are � examples of �PECT �efore �left panel� and early during 
treatment �i.e. ����8 h after start of therapy; right panel�. Upper 
panel: NHL treated �y low dose ��x� Gy� involved-field radiation. 
Middle panel: HN�CC treated �y cisplatin-�ased chemora-
diation. Lower panel: N�CLC treated �y cisplatin/gemcita�ine 
chemotherapy. Arrows indicate the target lesions. Note the physi-
ologic uptake in �ones and salivary glands �Modified from: Haas 
et al.� ���� [��] and Kartachova et al.� ���� [��]� Kartachova 
et al.� ���� [��]� and Verheij et al.� ���8 [��]
The investigators demonstrated increased ��mTc-
annexin V accumulation in lesions early during treat-
ment when compared to �aseline values in patients 
with complete or partial tumor remission� while there 
was no significant early increase in uptake in those pa-
tients with sta�le or progressive disease. This study es-
ta�lished ��mTc-annexin V scintigraphy as a predictive 
marker in tumor response. A su�sequent study from 
these authors evaluated the predictive value of TAV� 
in �� chemotherapy-naive patients with advanced 
stage N�CLC undergoing platinum-�ased chemo-
therapy. Also under these conditions� a significant 
correlation �etween annexin V changes and treatment 
outcome was found [��]. In a ���8 update of their 
study� Kartachova et al. [�5] showed that visual evalu-
ation of �PECT images� �PECT/�PECT and �PECT/
CT co-registered images correlated with quantitative 
analysis. Using �oth methods� all patients with early 
post-treatment increase in tumor uptake of ��mTc-an-
nexin V either developed complete response or partial 
response� resulting in statistically highly significant 
correlations �etween changes of ��mTc-annexin V tu-
mor uptake and therapeutic outcome for �oth visual 
and quantitative analysis. 
In addition to the monitoring of treatment-induced 
apoptosis in tumor cells� TAV� may also �e used 
to detect normal tissue toxicity. Hoe�ers et al. [��] 
applied ��mTc-annexin V scintigraphy to demonstrate 
apoptosis in patients with HN�CC� �oth in tumor 
and normal tissue. TAV� was performed �efore and 
within �8 h after the first course of cisplatin-�ased 
chemoradiation in �� patients. Already after a dose 
of ��8 Gy increased annexin V uptake was o�served 
in �� of the �� irradiated parotid glands. Glands� which 
received higher radiation dosages� showed more an-
nexin V uptake. The authors concluded that within 
the dose range of ��8 Gy� TAV� showed a radiation-
dose-dependent uptake in parotid glands� indicative 
of radiation-induced apoptosis. A similar pattern in the 
su�mandi�ular glands was o�served.
Limitations of annexin V imaging
Although TAV� appears very promising as an early 
predictor for tumor response to anticancer therapy� 
several limitations remain to firmly esta�lish its value 
as an imaging �iomarker of response. First of all� 
apoptosis is an acute event and contri�utes to early 
therapy-induced tumor shrinkage. Therefore� TAV� 
may �e less suita�le to predict long-term response 
to treatment [�����]. To determine whether this type 
of early cell death predicts long-term treatment out-
come parameters in patients� such as disease-free 
survival and overall survival� changes in TAV� uptake 
should �e correlated with tumor response measure-
ments after sufficiently long follow-up. �econdly� an-
nexin V �inding to P� does not discriminate �etween 
apoptotic and necrotic cell death as disrupted plasma 
mem�ranes also make P� accessi�le at the inner 
leaflet of cells undergoing necrosis. Thirdly� in terms 
of �iodistri�ution� annexin V has a relatively slow clear-
ing rate from non-targeted tissues� therefore creating 
a low signal-to-noise ratio [5�]. Fourthly� the optimal 
timing of apoptosis-imaging in vivo that yields most 
predictive information in terms of tumor response 
remains uncertain and should ideally �e determined 
for each specific tumor type and treatment moda-
lity. Multiple TAV� measurements may �e necessary 
to define this tumor- and/or therapy-specific optimal 
timing. Finally� apoptosis represents only one aspect 
of the complex �iological response to therapy� and 
its relative contri�ution varies among different tumor 
entities. More studies are needed to demonstrate the 
applica�ility of TAV�� especially in �solid� tumors that 
are therapy-resistant. Com�ining TAV� with other 
anatomical and functional imaging modalities may 
�e helpful in o�taining a more complete� and perhaps 
more solid �iomarker. 
OTHER RADIOTRACERS IN APOPTOSIS 
IMAGING 
Detection of apoptotic membrane imprint
The apoptotic mem�rane imprint is a complex of cel-
lular changes occurring in the plasma mem�rane early 
during the apoptotic process. These include irreversi�le 
loss of mem�rane potential� permanent acidification 
of the external plasma mem�rane leaflet and cytosol� 
and activation of g-scram�lase while preserving the 
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integrity of the plasma mem�rane. A set of novel small-
molecule pro�es designated the Aposense compounds 
�Aposense Ltd.� Petach-Tikva� Israel� have �een devel-
oped to detect these apoptosis-related plasma mem-
�rane alterations �see Fig. � [5�]�. This family of small 
molecules �DDC� ML-��� ML-�� N�T-���� and N�T-
���� have demonstrated activities in a num�er of tumor 
models in response to anticancer agents [5��5�]� 
however there is no clear mechanism of uptake of these 
compounds. The positron emission tomography �PET� 
tracer �8F-ML-�� shows selective uptake �y apoptotic 
cells in tumors following radio- and chemotherapy� cor-
relating with �reakdown of mitochondrial mem�rane 
potential� caspase activation and DNA degradation. 
As the signal is lost upon rupture of the plasma mem-
�rane� �8F-ML-�� should �e capa�le of discriminating 
apoptotic from necrotic cells [5�].
Recently� the role of �8F-ML-�� was evaluated 
in the early detection of response of �rain metasta-
ses to whole �rain irradiation ���x� Gy�. In this study 
�� patients underwent an �8F-ML-�� PET scan prior 
to treatment and a second scan after � or �� fractions 
of radiation. MRI was performed ��8 weeks after 
completion of treatment. In all �� patients� �oth MRI 
and the �8F-ML-�� PET scan detected all �rain lesions. 
A highly significant correlation was found �etween 
early changes on the �8F-ML-�� scan and later changes 
in tumor anatomical dimensions on MRI [55].
Methoxyisobutylisonitrile (MIBI) 
Technetium-��m methoxyiso�utylisonitrile ���mTc-
MIBI� is a lipophilic cation isonitrile compound that 
crosses the cell mem�rane due to the negative trans-
mem�rane potential and accumulates in mitochondria 
[5�� 5�]. Because of their higher meta�olic activity� 
tumor cells show large differences in mitochondrial 
mem�rane potential and high num�ers of mitochon-
dria� making ��mTc-MIBI an attractive agent in tumor 
imaging �see Fig. ��. Indeed� studies have demon-
strated that good responders of anti-tumor treatment 
display more MIBI accumulation as compared to poor 
responders in various tumor types� including small cell 
and non-small cell lung cancer [58���]� �reast cancer 
[�5]� malignant lymphoma [��]� osteosarcoma [��]� 
and nasopharyngeal carcinoma [�8]. One explanation 
for this phenomenon could �e the overexpression 
of the multidrug resistance gene �MDR��� which en-
codes P-glycoprotein �Pgp�� a transmem�rane protein 
that acts as an efflux pump to a wide range of cyto-
toxic drugs and ��mTc-MIBI [����5]� in chemotherapy 
resistant tumors. Another possi�ility is the inhi�ition 
of mitochondrial mem�rane permea�ility as a result 
of the overexpression of anti-apoptotic proteins 
such as Bcl-� [��� ��]. More recently� studies have 
esta�lished a correlation �etween ��mTc-MIBI tumor 
cell uptake and apoptosis after irradiation or che-
motherapy [�8� ��]. In an unpu�lished study� Del 
Vecchio et al. [��] demonstrated that the overex-
pression of Bcl-� which prevented ��mTc-MIBI uptake 
in untreated �reast carcinoma could �e counteracted 
�y the initiated drug therapy� allowing a transient in-
crease in ��mTc-MIBI accumulation. The authors specu-
lated that altered expression of proteins participating 
in the apoptotic process would affect mitochondrial 
permea�ility and transmem�rane potential� leading 
to a change in intracellular ��mTc-MIBI accumulation 
�oth prior to and after initiation of therapy. Further-
more� high levels of early ��mTc-MIBI uptake after 
treatment [8�]� could potentially indicate therapeutic 
efficacy. These results suggest that ��mTc-MIBI scin-
tigraphy has important clinical implications in pro-
viding prognostic information prior to treatment and 
also in monitoring effectiveness of treatment after 
initiation of anticancer therapy. 
Caspase-3 tracers
�everal groups have developed novel PET pro�es 
designed to non-invasively image caspase-� activa-
tion� including the small-molecule caspase inhi�itor� 
Isatin� used with different radioisotopes �see Fig. ��. 
�everal of these ��C or �8F Isatins examined in vivo 
[8��8�] demonstrated high affinity to caspase-� and 
high uptake in the liver in response to cycloheximide 
or anti-CD�5 anti�ody� confirmed �y immunohistol-
ogy of cell death. Although the radiola�eled Isatins 
appear to �ind specifically to caspase-�� their sen-
sitivity is limi ted� indicating that further optimization 
is required for clinical application of these tracers.
Coppola et al. [88] generated sta�le cell lines 
transfected with a hy�rid luciferase reported construct� 
which is activated �y caspase-� cleavage. Using 
this system� the apoptotic response of D5� glioma 
xenograft tumors to temozolomide and radiation was 
monitored �y detecting �ioluminescence emission. 
Apoptosis was detected within � h after � Gy of ra-
diation in mice receiving the com�ination treatment. 
Although this method appeared to �e very sensitive 
and quantitative� the experience seemed to �e lim-
ited to several animal models [85� 8�]. No pu�lished 
patient data are availa�le thus far. In addition� it has 
recently �een found that caspase-� activation is not 
unique to apoptosis [��� ��] and is involved in other 
physiological processes such as platelet aggregation 
and secretion of enzymes from pancreatic acinar cells. 
CONCLUDING REMARKS
This review focuses on in vivo apoptosis imag-
ing as a clinical �iomarker of response to treatment. 
In evaluating radiotracers for apoptosis imaging� there 
are a num�er of issues to consider. First� the tumor 
is heterogeneous and consists of a mixture of different 
cell types and no tracer discussed displays sufficient 
specificity to identify su�populations of tumor cells 
undergoing primary apoptosis. In fact� different types 
of cell death can �e induced �y anticancer therapy and 
exist within the same tumor� including “secondary” 
apoptosis due to incomplete DNA damage repair �after 
“mitotic death” or “mitotic catastrophe” or “reproduc-
tive cell death” [��� ��]�. �econd� �ecause response 
to therapy is tumor type-dependent� the optimal timing 
of in vivo imaging remains to �e defined. Though ��mTc-
annexin V scintigraphy has emerged as an attractive 
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candidate due to its predictive potential in treatment 
effectiveness in various tumor types� it is not an exclu-
sive marker for this type of cell death� as cellular ne-
crosis accommodates �inding of annexin V to exposed 
mem�rane P� as well. Therefore� further studies are 
needed to evaluate the applica�ility of this and other 
potential apoptotic markers in daily clinical practice. 
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